# US 2024/0197665 A1 · Pharmaceutical Composition For Treating Hyperlipidemia And Preparation Method Therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197665 A1
- Document ID: US20240197665A1
- Status: Published application
- Kind: A1
- Application number: 18/556,818
- Filed: 2022-05-09
- Published: 2024-06-20
- Earliest claimed: 2021-05-11
- Assignees: Sichuan Jiuzhang Biological Science and Technology Co., Ltd.
- Applicants: Sichuan Jiuzhang Biological Science and Technology Co., Ltd.
- Inventors: Jie ZHANG; Wenbin LI; Wang HUANG; Fei ZHANG; Ya ZHANG; Min XU
- Web page: https://patentgrep.com/patent/US20240197665A1

## CPC

- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 33/04: Sulfur, selenium or tellurium; Compounds thereof
- A61K 33/24: Heavy metals; Compounds thereof
- A61K 33/30: Zinc; Compounds thereof
- A61K 33/32: Manganese; Compounds thereof
- A61K 33/34: Copper; Compounds thereof
- A61P 3/06: Antihyperlipidemics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical composition for treating hyperlipidemia and a preparation method therefor are provided. The pharmaceutical composition contains chlorogenic acid, vitamins, pharmaceutically acceptable excipients and optional microelements. The pharmaceutical composition for treating hyperlipidemia reduce can serum total cholesterol and serum triglyceride, and increase the content of high-density lipoproteins.

## Claims

### Claim 1

A pharmaceutical composition for treating hyperlipidemia, characterized in that it comprises chlorogenic acid, vitamins, pharmaceutically acceptable excipients, and optional trace elements.

### Claim 2 (depends on 1)

The pharmaceutical composition for treating hyperlipidemia according to claim 1, characterized in that the pharmaceutical composition for treating hyperlipidemia comprises chlorogenic acid, vitamins, and optional trace elements as the only active ingredients.

### Claim 3 (depends on 1)

The pharmaceutical composition for treating hyperlipidemia according to claim 1, characterized in that the vitamin is selected from: vitamin C, vitamin E, vitamin B6, vitamin B12 or a combination thereof; preferably, the vitamin is selected from vitamin C.

### Claim 4 (depends on 1)

The pharmaceutical composition for treating hyperlipidemia according to claim 1, characterized in that the trace element is selected from: zinc, manganese, selenium, chromium, copper or a combination thereof; preferably, the trace element is selected from zinc gluconate, manganese gluconate, chromium chloride, copper gluconate or a combination thereof; more preferably, the trace element is selected from manganese gluconate.

### Claim 5 (depends on 1)

The pharmaceutical composition for treating hyperlipidemia according to claim 1, characterized in that the weight ratio of chlorogenic acid, vitamins, and optional trace elements is 100:(1-5):(0.01-0.05); preferably, the weight ratio of chlorogenic acid, vitamins, and optional trace elements is 100:(2-4):(0.02-0.04); more preferably, the weight ratio of chlorogenic acid, vitamins, and optional trace elements is 100:3:0.03.

### Claim 6 (depends on 1)

The pharmaceutical composition for treating hyperlipidemia according to claim 1, characterized in that the pharmaceutical composition for treating hyperlipidemia is administered by a gastroenteric or parenteral route, and preferably, the pharmaceutical formulation for gastrointestinal administration includes tablets, capsules, granules, and oral liquids, while the pharmaceutical formulation for parenteral administration includes injection, infusion solution, and freeze-dried powder injections.

### Claim 7 (depends on 1)

The preparation method of the pharmaceutical composition for treating hyperlipidemia according to claim 1, characterized in that it comprises the following steps:
(1) Each raw material is weighed according to the pre-determined amount;
(2) A pharmaceutical formulation for administration by the gastrointestinal or parenteral pathways is prepared according to conventional methods in this field.

### Claim 8

The combination of chlorogenic acid, vitamins, and optional trace elements for use in the manufacture of a pharmaceutical composition for treating hyperlipidemia.

### Claim 9 (depends on 8)

The use according to claim 8, characterized in that the vitamin is selected from: vitamin C, vitamin E, vitamin B6, vitamin B12 or a combination thereof, and the trace element is selected from: zinc, manganese, selenium, chromium, copper or a combination thereof.

### Claim 10 (depends on 9)

The use according to claim 9, characterized in that the weight ratio of chlorogenic acid, vitamins, and optional trace elements is 100:(1-5):(0.01-0.05).